The Parkinson\u2019s disease (PD) therapy market is changing: the first new levodopa formulation (Rytary) in over a decade launched in 2015 and\u00a0more are on the horizon (e.g., ND0612, IPX203);\u00a0two new rescue therapies for \u201coff\u201d periods are or soon will be available (i.e., Inbrija, APL-130277);\u00a0and several new adjunctive agents for motor and nonmotor symptoms have launched (i.e., Xadago, Ongentys, Gocovri, Nuplazid) or are in late-phase development (e.g., P2B001, TD-9855). These and other product launches will add another layer of complexity to an already complicated treatment algorithm with the potential to meaningfully increase sales of\u00a0PD\u00a0therapies. However, given the cost-sensitivity of PD patients and the widespread availability of generic and\u2014for many patients\u2014therapeutically adequate agents, new PD brands will enter a market of intensifying competition and access challenges.<\/p>\n
Questions Answered:<\/strong><\/p>\n What will be the impact of forthcoming levodopa reformulations?<\/p>\n Will they alter the PD treatment paradigm\u00a0or be sidelined by access hurdles and\/or physician resistance? What is the market opportunity for recently launched and emerging agents targeting key nonmotor symptoms in PD?<\/p>\n How do neurologists differentiate among\u00a0levodopa-adjunct therapies for motor fluctuations and dyskinesia, and which of these therapies will enjoy the greatest clinical and commercial success in this highly generic market?<\/p>\n Markets covered<\/strong>:<\/p>\n United States, France, Germany, Italy, Spain, United Kingdom, Japan.Primary research: 32 country-specific interviews with thought-leading neurologists; supported by survey data collected for this and other DRG research.<\/p>\n Epidemiology: Total, diagnosed, and drug-treated prevalent cases of PD by country.<\/p>\n Emerging therapies: Phase II: 24\u00a0drugs; Phase III: 6\u00a0drugs; preregistration: 1 drug.<\/p>\n Market forecast features: Ten-year, annualized, drug-level sales and patient shares of key PD therapies through 2028, segmented by brands\/generics.<\/p>\n Key companies: AbbVie, Acadia Pharmaceuticals, Acorda Therapeutics,\u00a0Adamas Pharmaceuticals, Amneal Pharmaceuticals, Eisai, Hisamitsu\u00a0Pharmaceutical,\u00a0Kyowa\u00a0Hakko Kirin, Meiji Seika\u00a0Pharma, Mitsubishi Tanabe Pharma, Newron\u00a0Pharmaceuticals, NeuroDerm, Osmotica Pharmaceuticals,\u00a0Pharma\u00a0Two B, Sumitomo Dainippon Pharma, Sunovion,\u00a0Takeda, Teva, Theravance\u00a0Biopharma, UCB, US WorldMeds, Zambon Pharma.Key drugs: levodopa, amantadine, ampreloxetine, apomorphine, ABBV-951,\u00a0AP-CD\/LD,\u00a0APL-130277, Duodopa\/Duopa, entacapone, Gocovri,\u00a0Haruropi Tape, Inbrija, IPX203, ND0612, Neupro, Nourianz, Nuplazid, Ongentys, Osmolex ER,\u00a0pramipexole,\u00a0P2B001, rasagiline, ropinirole, Rytary, selegiline, Trerief,\u00a0Xadago.<\/p>\n","protected":false},"template":"","class_list":["post-390333","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-parkinsons-disease","biopharma-date-931"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390333","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390333\/revisions"}],"predecessor-version":[{"id":393458,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390333\/revisions\/393458"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390333"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}